[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]

Year

Day

August 16, 2017
Original Investigation

Comparison of Coronary CT Angiography, SPECT, PET, and Hybrid Imaging for Diagnosis of Ischemic Heart Disease Determined by Fractional Flow Reserve

Abstract Full Text
free access
JAMA Cardiol. Published online August 16, 2017. doi:10.1001/jamacardio.2017.2471

This head-to-head comparative study evaluates the diagnostic accuracy of coronary computed tomography angiography, single-photon emission tomography, and positron emission tomography and explores the incremental value of hybrid imaging compared with fractional flow reserve.

Viewpoint

Balanced Adoption of Radial Artery Access for Primary Percutaneous Coronary Intervention

Abstract Full Text
JAMA Cardiol. Published online August 16, 2017. doi:10.1001/jamacardio.2017.2346

This Viewpoint discusses the need for determining an optimal balance between femoral and radial artery access in primary percutaneous coronary intervention.

Incentivizing Transradial Access for Primary Percutaneous Coronary Intervention While Maintaining Timely Reperfusion

Abstract Full Text
JAMA Cardiol. Published online August 16, 2017. doi:10.1001/jamacardio.2017.2348

This Viewpoint discusses a proposal to incentivize adopting transradial rather than transfemoral access for primary percutaneous coronary intervention to improve processes of care in patients with ST-segment elevation myocardial infarction.

Invited Commentary

SPECT, PET, and CTA—Acronyms or Better Imaging?

Abstract Full Text
JAMA Cardiol. Published online August 16, 2017. doi:10.1001/jamacardio.2017.2588
Comment & Response

PCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicity

Abstract Full Text
JAMA Cardiol. Published online August 16, 2017. doi:10.1001/jamacardio.2017.2727

PCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicity—Reply

Abstract Full Text
JAMA Cardiol. Published online August 16, 2017. doi:10.1001/jamacardio.2017.2734
August 9, 2017
Original Investigation

Temporal Changes in the Racial Gap in Survival After In-Hospital Cardiac Arrest

Abstract Full Text
JAMA Cardiol. Published online August 9, 2017. doi:10.1001/jamacardio.2017.2403

This study examines whether racial differences in survival after in-hospital cardiac arrest have changed over time and whether these differences could be explained by acute resuscitation survival, postresuscitation survival, and/or greater temporal improvement in survival at hospitals with higher proportions of black patients.

Brief Report

Intraoperative Diagnosis of Anderson-Fabry Disease in Patients With Obstructive Hypertrophic Cardiomyopathy Undergoing Surgical Myectomy

Abstract Full Text
JAMA Cardiol. Published online August 9, 2017. doi:10.1001/jamacardio.2017.2353

This case series examines a series of patients diagnosed with hypertrophic cardiomyopathy and severe basal left ventricular outflow tract obstruction undergoing myectomy in whom the diagnosis of Anderson-Fabry cardiomyopathy was suspected by the cardiac surgeon intraoperatively and confirmed by histological and genetic examinations.

Viewpoint

The Benefit Model for Prevention of Cardiovascular DiseaseAn Opportunity to Harmonize Guidelines

Abstract Full Text
JAMA Cardiol. Published online August 9, 2017. doi:10.1001/jamacardio.2017.2543

This Viewpoint discusses the benefit model vs risk-based prevention strategies for cardiovascular disease.

Invited Commentary

Racial Differences in In-Hospital Cardiac ArrestGood News: Cautious Optimism Is Welcome

Abstract Full Text
JAMA Cardiol. Published online August 9, 2017. doi:10.1001/jamacardio.2017.2432
Review

Role of Genetic Testing in Inherited Cardiovascular DiseaseA Review

Abstract Full Text
JAMA Cardiol. Published online August 9, 2017. doi:10.1001/jamacardio.2017.2352

This review provides an overview of the role of genetic testing for inherited cardiovascular disease among at-risk patients and their relatives, with considerations to successfully integrate genetic testing into clinical practice.

Editor's Note

Incorporating Genetic Testing Into Cardiovascular Practice

Abstract Full Text
JAMA Cardiol. Published online August 9, 2017. doi:10.1001/jamacardio.2017.2626
August 2, 2017
Original Investigation

Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease

Abstract Full Text
open access
JAMA Cardiol. Published online August 2, 2017. doi:10.1001/jamacardio.2017.2289

This simulation model study estimates the percentage of patients with atherosclerotic cardiovascular disease who would require proprotein convertase subtilisin/kexin type 9 inhibitor therapy when oral therapy to lower lipid levels is intensified first.

Temporal Relation Between Myocardial Fibrosis and Heart Failure With Preserved Ejection FractionAssociation With Baseline Disease Severity and Subsequent Outcome

Abstract Full Text
JAMA Cardiol. Published online August 2, 2017. doi:10.1001/jamacardio.2017.2511

This cohort study investigates whether myocardial fibrosis is similarly prevalent in both those with heart failure with preserved ejection fraction (HFpEF) and those at risk for HFpEF, similarly associating with disease severity and outcomes.

Viewpoint

Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease RiskWhere Do We Stand?

Abstract Full Text
JAMA Cardiol. Published online August 2, 2017. doi:10.1001/jamacardio.2017.2288

This Viewpoint summarizes the debate surrounding the LDL hypothesis and suggests next steps for better reducing atherosclerotic cardiovascular disease risk.

Low-Density Lipoprotein Cholesterol Treatment in the Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor EraGetting Back on Target

Abstract Full Text
JAMA Cardiol. Published online August 2, 2017. doi:10.1001/jamacardio.2017.2293

This Viewpoint summarizes treatment options for lowering low-density lipoprotein cholesterol levels, specifically the effects of adding additional drugs to statin therapy.

Editorial

Defining Potential Use of Nonstatin Therapies to Lower Blood Cholesterol Levels

Abstract Full Text
JAMA Cardiol. Published online August 2, 2017. doi:10.1001/jamacardio.2017.2290
Special Communication

Effects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart FailureProposal of a Novel Mechanism of Action

Abstract Full Text
JAMA Cardiol. Published online August 2, 2017. doi:10.1001/jamacardio.2017.2275

This Special Communication examines the results of clinical trials to determine the benefit of sodium-glucose cotransporter 2 inhibitors on heart failure among patients with diabetes.

JAMA Cardiology Clinical Guidelines Synopsis

Guidelines Update on Indications for Transcatheter Aortic Valve Replacement

Abstract Full Text
JAMA Cardiol. Published online August 2, 2017. doi:10.1001/jamacardio.2017.2546

This article summarizes the guideline updates on indications for transcatheter aortic valve replacement.

×